
A multicenter, randomized trial evaluated the safety and efficacy of a novel lipid-containing eye drop (BTC) in treating dry eye disease (DED) symptoms. The study, involving 158 subjects, compared BTC to a commercially available non-lipid eye drop (NLED). Results showed that BTC improved ocular comfort scores significantly more than the comparator over a 30-day period, meeting noninferiority criteria. Both treatments were well tolerated with no significant adverse events, making BTC a potential effective therapy for DED patients who benefit from lipid-based artificial tears.
Like
Save
Share